| Joel Neilson Bahm, | |
|
2003 Sheffield Rd Ste C, Aliquippa, PA 15001-2758 | |
| (866) 444-6290 | |
| (877) 486-4545 |
| Full Name | Joel Neilson Bahm |
|---|---|
| Gender | Male |
| Speciality | Pharmacist |
| Location | 2003 Sheffield Rd Ste C, Aliquippa, Pennsylvania |
| Accepts Medicare Assignments | Does not participate in Medicare Program. He may not accept medicare assignment. |
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1760023105 | NPI | - | NPPES |
| 1007458630052 | Medicaid | PA |
| Taxonomy | Type | License (State) | Status |
|---|---|---|---|
| 183500000X | Pharmacist | RP031072L (Pennsylvania) | Primary |
| Mailing Address | Practice Location Address |
|---|---|
| Joel Neilson Bahm, 2003 Sheffield Rd Ste C, Aliquippa, PA 15001-2799 Ph: (866) 444-6290 | Joel Neilson Bahm, 2003 Sheffield Rd Ste C, Aliquippa, PA 15001-2758 Ph: (866) 444-6290 |
News Archive
Health Discovery Corporation announced today that the Company has entered into an exclusive agreement with the Pancreas, Biliary and Liver Surgery Center of New York at Saint Vincent Catholic Medical Centers in New York City to provide clinical specimens to be utilized to complete the final validation of HDC's molecular diagnostic test for colon cancer. This test demonstrated a 93% Sensitivity and a 93% Specificity in a previous validation study.
Myriad Genetics has announced the issuance of Patent No. 6,911,466 entitled, "AB42 Lowering Agents". Myriad holds exclusive rights to the patent under a licensing agreement with Mayo Clinic. The patent covers methods of using a broad class of compounds known as selective amyloid beta 42 lowering agents (SALAs) to lower levels of the toxic peptide.
Frank Stonebanks, Vice-President, Commercialization and Chief Commercial Officer of the Ontario Institute for Cancer Research today announced that OICR has made equity investments in three promising Ontario technologies to accelerate their commercialization.
A new report published by WHO in the lead-up to World Diabetes Day highlights the alarming state of global access to insulin and diabetes care, and finds that high prices, low availability of human insulin, few producers dominating the insulin market and weak health systems are the main barriers to universal access.
Richard Gershon has a shiny new toolbox for neuroscientists that will revolutionize their clinical research by making it radically faster, cheaper and more accurate. It also will help researchers recruit children and adults for studies because participation will be much less time consuming.
› Verified 1 days ago
Mrs. Antoniette Barbuto, RPH Pharmacist Medicare: Not Enrolled in Medicare Practice Location: 2665 Brodhead Rd, Suite B, Aliquippa, PA 15001 Phone: 724-375-1230 | |
Lori Zelesnik, Pharmacist Medicare: Not Enrolled in Medicare Practice Location: 143 Turkmar Dr, Aliquippa, PA 15001 Phone: 724-775-5325 | |
Adam Andrew, Pharmacist Medicare: Not Enrolled in Medicare Practice Location: 2003 Sheffield Rd, Aliquippa, PA 15001 Phone: 180-085-0339 | |
Mrs. Heather Walsh, RPH Pharmacist Medicare: Not Enrolled in Medicare Practice Location: 2665 Brodhead Rd, Aliquippa, PA 15001 Phone: 724-378-4141 | |
Mr. Gino S. Cordisco, R.PH. Pharmacist Medicare: Not Enrolled in Medicare Practice Location: 2003 Sheffield Rd, Aliquippa, PA 15001 Phone: 724-816-2512 Fax: 724-776-7237 | |
Douglas Kaleugher, RPH Pharmacist Medicare: Not Enrolled in Medicare Practice Location: 2003 Sheffield Rd, Aliquippa, PA 15001 Phone: 724-378-5325 Fax: 724-378-5312 | |
James Conrad Burke, RPH Pharmacist Medicare: Not Enrolled in Medicare Practice Location: 2003 Sheffield Rd, Suite B, Aliquippa, PA 15001 Phone: 724-375-1672 |